Chunming Jiang1, Fang Shen2, Jianmin Du1, Xiaohua Wang3, Jin Su4, Zhanli Liu1, Xianmei Huang1. 1. Department of Pediatrics, Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou First People's Hospital Hangzhou 301103, Zhejiang, P. R. China. 2. Department of psychiatry, Tongde Hospital of Zhejiang Province Hangzhou 301103, Zhejiang, P. R. China. 3. Nanjing First Hospital, Nanjing Medical University Nanjing 210029, Jiangsu, P. R. China. 4. Department of Pediatrics, The First Affiliated Hospital of Nanjing Medical University Nanjing 210029, Jiangsu, P. R. China.
Abstract
BACKGROUND: Excision repair cross complementation group 1 (ERCC1) has been shown to be involved in the progression of glioma susceptibility. However, the results remain conflict. The aim of this study was to systematically review and evaluate the role of ERCC1 C118T and C8092A polymorphisms in glioma risk among Chinese population. METHODS: Related case-control studies were searched in online electronic databases. Odds ratio (OR) with its 95% confidence interval (CI) were employed to calculate the extracted data. RESULTS: Total seven articles were retrieved, including 4426 subjects (1926 were glioma patients and 2500 were matched controls). No significant heterogeneity was found between studies (I(2)=0%, P>0.01). Our results demonstrated that A allele and AA genotype of ERCC1 C8092A polymorphism have a positive association with increasing the risk of glioma in the fixed-effect model (A vs. C: OR=1.13, 95% CI=1.02-1.25, P=0.02; AA vs. CC: OR=1.29, 95% CI=1.04-1.61, P=0.02; AA vs. CA+CC: OR=1.25, 95% CI=1.01-1.55, P=0.04). However, no significant relationship was found between C118T variant and glioma susceptibility. CONCLUSIONS: Our results indicated that ERCC1 C8092A, not C118T polymorphism might be a biomarker for patients with glioma among Chinese population. Future studies with more ethnicities are needed to explore the precise association.
BACKGROUND:Excision repair cross complementation group 1 (ERCC1) has been shown to be involved in the progression of glioma susceptibility. However, the results remain conflict. The aim of this study was to systematically review and evaluate the role of ERCC1C118T and C8092A polymorphisms in glioma risk among Chinese population. METHODS: Related case-control studies were searched in online electronic databases. Odds ratio (OR) with its 95% confidence interval (CI) were employed to calculate the extracted data. RESULTS: Total seven articles were retrieved, including 4426 subjects (1926 were gliomapatients and 2500 were matched controls). No significant heterogeneity was found between studies (I(2)=0%, P>0.01). Our results demonstrated that A allele and AA genotype of ERCC1C8092A polymorphism have a positive association with increasing the risk of glioma in the fixed-effect model (A vs. C: OR=1.13, 95% CI=1.02-1.25, P=0.02; AA vs. CC: OR=1.29, 95% CI=1.04-1.61, P=0.02; AA vs. CA+CC: OR=1.25, 95% CI=1.01-1.55, P=0.04). However, no significant relationship was found between C118T variant and glioma susceptibility. CONCLUSIONS: Our results indicated that ERCC1C8092A, not C118T polymorphism might be a biomarker for patients with glioma among Chinese population. Future studies with more ethnicities are needed to explore the precise association.
Entities:
Keywords:
DNA repair gene; ERCC1; Glioma; meta-analysis; polymorphism
Authors: Andreas Woelfelschneider; Odilia Popanda; Carmen Lilla; Jakob Linseisen; Claudia Mayer; Oktay Celebi; Jürgen Debus; Helmut Bartsch; Jenny Chang-Claude; Peter Schmezer Journal: Carcinogenesis Date: 2008-03-10 Impact factor: 4.944